Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.63
- Piotroski Score 3.00
- Grade Equal-Weight
- Symbol (AVTE)
- Company Aerovate Therapeutics, Inc.
- Price $2.72
- Changes Percentage (-0.04%)
- Change -$0
- Day Low $2.67
- Day High $2.73
- Year High $32.42
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $2.00
- High Stock Price Target $35.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.03
- Trailing P/E Ratio -6.84
- Forward P/E Ratio -6.84
- P/E Growth -6.84
- Net Income $-75,521,000
